Urolithin A has been investigated in human studies of mitochondrial biology and muscle function. For a supplement project, the next step is to connect that evidence with a defined consumer group, a workable formulation and a qualified ingredient supply. [3][4][5]
This guide explains what Urolithin A is, how to interpret the research and what to review before ordering bulk raw material. It gives brand owners, formulators and distributors a common starting point for product development and supplier discussions.
Illustrative raw-material scene.
Urolithin A, often abbreviated to UA, is a metabolite that certain gut microorganisms can produce from ellagic acid and ellagitannins. These precursor compounds occur in foods such as pomegranates, some berries and walnuts. The ability to produce UA varies with the gut microbiome. [1]
A standardized Urolithin A ingredient supplies a defined quantity of the compound directly. Pomegranate extract, ellagic acid and purified UA therefore need to be evaluated as distinct ingredient options. A botanical extract specification does not establish how much UA a person will produce after consuming it. [1]
For sourcing, confirm the material’s identity, manufacturing route, analytical specification and intended use. The fact that UA occurs as a human metabolite does not identify how a particular commercial powder was manufactured.
Mitochondria participate in cellular energy production. Cells maintain their mitochondrial population partly through mitophagy, a process that removes damaged or dysfunctional mitochondria. Preclinical work has examined UA as a mitophagy inducer and reported effects on mitochondrial quality and muscle function in animal models. [2]
Human research has subsequently assessed mitochondrial biomarkers and selected measures of muscle performance. These findings give product developers a basis for evaluating muscle health and healthy aging concepts, with claims tied to the specific human evidence. [3][4][5]
Three foundational trials illustrate why study design matters when assessing Urolithin A. The doses below describe research protocols; a finished product’s use level also requires a separate safety, formulation and regulatory assessment.
Healthy sedentary older adults. Multiple-dose treatment for four weeks, including 500 and 1,000 mg per day.
Favorable tolerability in the trial and changes in mitochondrial biomarkers. This was an early safety and biological-activity study. [3]
66 adults aged 65–90. 1,000 mg per day or placebo for four months.
Selected hand and leg muscle endurance measures improved at two months. The primary walking-distance and hand-muscle ATP outcomes were not significantly different from placebo. [4]
88 middle-aged adults. 500 or 1,000 mg per day or placebo for four months.
Hamstring strength improved versus placebo. The primary endpoint of peak power output did not improve significantly. [5]
Review study methods, statistical comparisons and disclosures. Several trials involved the ingredient developer. Findings concern the specific materials and formulations tested; equivalence with a new supplier’s material needs separate substantiation. [3][4][5]
For a brand, the practical task is to define a claim that fits the intended audience and the available evidence. For a manufacturer, it is to establish a formulation and test plan capable of supporting that product brief.
For additional background, read our article on Urolithin A and healthy aging.
A healthy aging concept can focus development discussions on maintaining muscle function and everyday physical activity in the population the brand intends to serve. The evidence review should consider how closely that population matches the participants in relevant studies.
For a sports nutrition concept, define the desired outcome precisely. Strength, muscle endurance, recovery and whole-body exercise performance are different endpoints. Select supporting studies and a validation plan for the particular outcome being considered.
Distributors can use the same approach when qualifying downstream opportunities. A useful customer brief identifies the destination market, product format, target user, proposed use level and expected purchasing volume. These details make technical and commercial discussions more productive.
Begin with the intended serving size and finished format. The research dose, the amount of raw powder added and the labeled quantity of active compound must be reconciled using an appropriate quantitative assay. Review the test method and reporting basis before converting raw-material weight into active content.
Formulation formats require project-specific feasibility and stability testing.
Can the intended serving fit the format? Evaluate blend uniformity, powder handling, disintegration or dissolution, and excipient compatibility.
Assess segregation, dose uniformity, moisture control and how the consumer prepares the product.
Check achievable loading, uniformity, processing conditions, sensory performance and retention during storage.
Test solubility or suspension behavior at the intended concentration, alongside sedimentation, pH, processing and shelf-life performance.
Distinguish solubility, dispersibility and bioavailability. A powder that disperses more evenly may be easier to process, while a claim about improved human absorption requires appropriate pharmacokinetic evidence. A delivery-system name, such as liposomal, is not sufficient evidence of better uptake.
Treat raw-material and finished-product stability as separate questions. Establish suitable packaging and storage conditions, then verify the finished formula through relevant stability testing. If UA is combined with other ingredients, evaluate their compatibility and the evidence for the combination.
Illustrative laboratory scene for analytical evaluation.
Before comparing commercial offers, ask suppliers to quote against the same specification. Review identity testing, quantitative assay, the meaning of the reported purity value and batch-specific acceptance limits. Depending on the process and intended use, the review may also include related substances, residual solvents, elemental impurities and microbiological testing.
The analytical method matters. An HPLC area percentage and a validated mass-based assay can answer different questions. Request clarification on calibration, reporting basis and the treatment of moisture so that different offers can be compared meaningfully.
For U.S. projects, assess the ingredient’s intended use and the applicable regulatory route. FDA’s public GRAS Notice 791 identifies Amazentis SA as the notifier and records a “no questions” response for the uses described in that submission. Buyers need to establish whether the supporting documentation is relevant to their particular material, manufacturing process, specification and use. [6]
Dietary supplement projects also require assessment of dietary ingredient status and any applicable new dietary ingredient notification obligations. FDA places responsibility for ingredient safety on the relevant manufacturers and distributors. Review these questions with the team responsible for the finished product’s market access. [7]
Supplier qualification should cover traceability, manufacturing and testing responsibilities, change notification, sample-to-production consistency and delivery planning. Verify the scope and validity of any facility certificates, and review intellectual property relevant to the planned commercial use.
Compare cost at the level of the finished serving as well as per kilogram. Specify the required assay, intended active quantity, batch size, testing requirements and packaging. Processing losses, freight, import costs and inventory needs can also affect the commercial calculation.
A distributor may need documentation suitable for several downstream customers, while an OEM may need repeatable powder properties for a particular production line. Include those requirements in the request for quotation so the sample evaluation and commercial offer address the same brief.
UUBiotech supplies Urolithin A raw material for business customers evaluating supplement and related ingredient projects. Our published product page lists the following specification details.
Product name: Urolithin A
CAS number: 1143-70-0
Purity: ≥98.0% by HPLC
Appearance: Light yellow powder
View the UUBiotech Urolithin A product page and request the latest specification and a relevant batch COA for your assessment.
To discuss a sample or bulk requirement, share your company name, destination market, intended format, required specification and estimated quantity. Please also indicate whether the project is at laboratory evaluation, pilot production or commercial purchasing stage.
For specifications, sample discussions and quotations, submit your Urolithin A inquiry or contact sales@uubiotech.com.
2.Ryu D et al. Preclinical research on urolithin A and mitophagy. Nature Medicine. 2016;22:879–888.
3.Andreux PA et al. First human trial of urolithin A. Nature Metabolism. 2019;1:595–603.
5.Singh A et al. Urolithin A in middle-aged adults. Cell Reports Medicine. 2022;3(5):100633.
8.Youyou Biotechnology. Urolithin A product page.
